LADASTEN
Russian adamantane-derived atypical stimulant with anxiolytic properties, used for asthenic disorders and neurasthenia.
Ladasten was developed in Russia as an antiasthenic drug combining psychostimulant and anxiolytic effects, an unusual profile for a stimulant. A pilot clinical trial demonstrated efficacy in patients with psychogenic asthenic disorder, with predominant stimulant action and good tolerability. Animal studies show it differentially regulates tyrosine hydroxylase and dopamine content across brain regions and reinforces hippocampal long-term potentiation. It also shows anti-inflammatory effects superior to imipramine in reducing TNF-α and IL-6 in an LPS-induced depression model. However, clinical evidence is limited primarily to Russian trials, and no large-scale Western randomized controlled trials have been published.